Lisanti Capital Growth LLC Invests $3.13 Million in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Lisanti Capital Growth LLC purchased a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 105,895 shares of the medical device company's stock, valued at approximately $3,132,000. Lisanti Capital Growth LLC owned approximately 0.16% of Tandem Diabetes Care at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. M&T Bank Corp boosted its position in Tandem Diabetes Care by 118.7% during the fourth quarter. M&T Bank Corp now owns 49,649 shares of the medical device company's stock worth $1,469,000 after purchasing an additional 26,943 shares in the last quarter. Natixis Advisors L.P. purchased a new position in Tandem Diabetes Care during the fourth quarter worth approximately $1,025,000. Van ECK Associates Corp boosted its position in Tandem Diabetes Care by 8.6% during the fourth quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company's stock worth $175,000 after purchasing an additional 467 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Tandem Diabetes Care by 79.5% during the fourth quarter. Russell Investments Group Ltd. now owns 247,325 shares of the medical device company's stock worth $7,316,000 after purchasing an additional 109,505 shares in the last quarter. Finally, Truist Financial Corp purchased a new position in Tandem Diabetes Care during the fourth quarter worth approximately $2,588,000.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TNDM. SVB Leerink upgraded Tandem Diabetes Care from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $34.00 to $45.00 in a research report on Thursday, April 25th. Piper Sandler reissued an "overweight" rating and set a $50.00 target price (up previously from $35.00) on shares of Tandem Diabetes Care in a report on Friday. Citigroup increased their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a report on Wednesday, April 3rd. Barclays increased their target price on Tandem Diabetes Care from $39.00 to $55.00 and gave the company an "overweight" rating in a report on Monday. Finally, Stifel Nicolaus increased their target price on Tandem Diabetes Care from $37.00 to $40.00 and gave the company a "buy" rating in a report on Tuesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

Tandem Diabetes Care Trading Down 2.7 %

Tandem Diabetes Care stock traded down $1.22 during mid-day trading on Monday, hitting $43.50. The company's stock had a trading volume of 1,498,367 shares, compared to its average volume of 1,770,159. Tandem Diabetes Care, Inc. has a 1 year low of $13.82 and a 1 year high of $47.00. The stock's fifty day moving average is $32.58 and its two-hundred day moving average is $26.35. The firm has a market capitalization of $2.81 billion, a PE ratio of -20.05 and a beta of 1.10. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. The firm had revenue of $196.80 million for the quarter, compared to analysts' expectations of $204.86 million. On average, analysts anticipate that Tandem Diabetes Care, Inc. will post -1.62 EPS for the current year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.